首页> 美国卫生研究院文献>The Oncologist >Phase I Study of Pazopanib in Combination with Weekly Paclitaxel in Patients with Advanced Solid Tumors

【2h】

Phase I Study of Pazopanib in Combination with Weekly Paclitaxel in Patients with Advanced Solid Tumors

机译：帕唑帕尼联合每周紫杉醇治疗晚期实体瘤的I期研究

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

Purpose.To evaluate the maximum tolerated regimen (MTR), dose-limiting toxicities, and pharmacokinetics of pazopanib, an oral small-molecule tyrosine kinase inhibitor of vascular endothelial growth factor receptor, platelet-derived growth factor receptor, and c-Kit, in combination with paclitaxel.

机译：目的：评估口服血管内皮生长因子受体，血小板衍生的生长因子受体和c-Kit的口服小分子酪氨酸激酶抑制剂帕唑帕尼的最大耐受方案（MTR），剂量限制性毒性和药代动力学与紫杉醇合用。

著录项

期刊名称 The Oncologist
作者
Antoinette R. Tan; Afshin Dowlati; Suzanne F. Jones; Jeffrey R. Infante; Jennifer Nishioka; Lei Fang; Jeffrey P. Hodge; Shelby D. Gainer; Thangam Arumugham; A. Benjamin Suttle; Mohammed M. Dar; Joanne J. Lager; Howard A. Burris III;
展开▼
作者单位

展开▼
年(卷),期 2010(15),12
年度 2010
页码 1253–1261
总页数 9
原文格式 PDF
正文语种
中图分类肿瘤学 ;
关键词
Pazopanib Paclitaxel Vascular endothelial growth factor receptor tyrosine kinase inhibitor;

机译：帕唑帕尼;紫杉醇;血管内皮生长因子受体酪氨酸激酶抑制剂;

相似文献

外文文献
中文文献
专利

1. Phase I study of pazopanib in combination with weekly paclitaxel in patients with advanced solid tumors. [J] . Tan AR, Dowlati A, Jones SF, The oncologist . 2010 ,第12期

机译：帕唑帕尼联合每周紫杉醇治疗晚期实体瘤的I期研究。
2. Phase I Study of Pazopanib in Combination with Weekly Paclitaxel in Patients with Advanced Solid Tumors [J] . A. Benjamin Suttle, Afshin Dowlati, Antoinette R. Tan, The oncologist . 2010 ,第12期

机译：帕唑帕尼联合每周紫杉醇治疗晚期实体瘤的I期研究
3. A Multicenter Phase I Study of Pazopanib in Combination with Paclitaxel in First-Line Treatment of Patients with Advanced Solid Tumors [J] . Kendra Kari L., Plummer Ruth, Salgia Ravi, Molecular cancer therapeutics . 2015 ,第2期

机译：帕唑帕尼联合紫杉醇一线治疗晚期实体瘤患者的多中心I期研究
4. Phase I/II clinical trials on the effect of weekly paclitaxel (wPTX) and wPTX containing combination regimens for advanced and metastatic gastric cancer -ECRIN group studies [C] . Sakamoto J, Kodera Y, Kobayashi M, International Gastric Cancer Congress . 2009

机译：I / II期临床试验关于每周紫杉醇（WPTX）和WPTX含有晚期和转移性胃癌组合方案的临床试验 - 分泌组研究
5. A phase I study of vincristine, escalating doses of irinotecan, temozolomide and bevacizumab (VIT-B) in pediatric and adolescent patients with recurrent or refractory solid tumors of non-hematopoietic origin [D] . Venkatramani, Rajkumar. 2010

机译：长春新碱，伊非替康，替莫唑胺和贝伐单抗（VIT-B）逐步剂量在患有非造血源性复发或难治性实体瘤的儿童和青少年患者中的I期研究
6. Phase I study of weekly paclitaxel in combination with pazopanib and lapatinib in advanced solid malignancies [O] . A R Tan, A Dowlati, M N Stein, 2014

机译：每周紫杉醇联合帕唑帕尼和拉帕替尼治疗晚期实体瘤的I期研究
7. Phase I Study of Pazopanib in Combination with Weekly Paclitaxel in Patients with Advanced Solid Tumors [O] . Tan, Antoinette R., Dowlati, Afshin, Jones, Suzanne F., 2010

机译：帕唑帕尼联合每周紫杉醇治疗晚期实体瘤的I期研究

Phase I Study of Pazopanib in Combination with Weekly Paclitaxel in Patients with Advanced Solid Tumors

摘要

著录项

相似文献

相关主题

期刊订阅